On May 20, 2022, Kintara Therapeutics, Inc. (the Company) and Saiid Zarrabian, the Company's Head of Strategic Partnerships and a member of the Board of Directors (the Board) of the Company, mutually agreed that Mr. Zarrabian would step down from his role as Head of Strategic Partnerships and as a member of the Board, effective as of May 23, 2022 (the Separation Date) to pursue other opportunities. Mr. Zarrabian's separation was not the result of any disagreements with the Company relating to the Company's operations, policies or practices. In connection with Mr. Zarrabian's separation from the Company, on May 20, 2022, the Company and Mr. Zarrabian entered into a separation and general release agreement (the Separation Agreement).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1493 USD | -4.05% | -1.32% | -11.97% |
Apr. 03 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 03 | Sector Update: Health Care | MT |
1st Jan change | Capi. | |
---|---|---|
-11.97% | 8.26M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KTRA Stock
- News Kintara Therapeutics, Inc.
- Saiid Zarrabian to Step Down from His Role as Head of Strategic Partnerships and as A Member of the Board of Kintara Therapeutics